Alexandra Zduniak, Jérémie Martinet, Emilie Lévêque, Stéphanie Becker, David Tonnelet, Elodie Dos Santos, Claire Leroy, Mustafa Alani, Jean Rouvet, Marine Brousseau, Camille Giverne, Alexis Cuffel, Serge Jacquot, Arnaud Roucheux, Alice Veuiller, Nicolas Lecornu, Misa Eugene Norbert, Olivier Boyer, Hervé Tilly, Fabrice Jardin, Jean-Baptiste Latouche, Vincent Camus
{"title":"流式细胞术常规监测侵袭性大b细胞淋巴瘤患者car - t细胞扩增和持续性：单中心经验","authors":"Alexandra Zduniak, Jérémie Martinet, Emilie Lévêque, Stéphanie Becker, David Tonnelet, Elodie Dos Santos, Claire Leroy, Mustafa Alani, Jean Rouvet, Marine Brousseau, Camille Giverne, Alexis Cuffel, Serge Jacquot, Arnaud Roucheux, Alice Veuiller, Nicolas Lecornu, Misa Eugene Norbert, Olivier Boyer, Hervé Tilly, Fabrice Jardin, Jean-Baptiste Latouche, Vincent Camus","doi":"10.1002/hon.70139","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>This retrospective, single-center study evaluated routine flow cytometry (FC) monitoring of CAR-T-cells in 45 patients with aggressive large B-cell lymphoma (LBCL). CAR-T-cells expansion was assessed from Day 0 to Month 12. Peak expansion occurred on Day 7 after axi-cel (median 39.3% of total lymphocytes; 87 cells/mm<sup>3</sup>) and Day 10 for tisa-cel (median 8.1%; 33.2 cells/mm<sup>3</sup>). Greater CAR-T-cells expansion was associated with immune-related toxicity, with median peak levels reaching 52.8% in patients with grade 2 cytokine release syndrome (CRS) versus 6.6% in those without (<i>p</i> < 0.001) and 60.8% in patients with immune effector cell-associated neurotoxicity syndrome (ICANS) versus 15.3% in those without (<i>p</i> < 0.001). Prolonged cytopenia was observed in 65% of patients and more frequently among those with greater CAR-T-cells expansion. This study highlights FC as a practical tool for monitoring CAR-T-cells dynamics in routine practice, with potential implications for early toxicity risk assessment and personalized supportive care.</p>\n </section>\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 6","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70139","citationCount":"0","resultStr":"{\"title\":\"Routine Monitoring of CAR-T-Cells Expansion and Persistence in Patients With Aggressive Large B-Cell Lymphoma by Flow Cytometry: A Single-Center Experience\",\"authors\":\"Alexandra Zduniak, Jérémie Martinet, Emilie Lévêque, Stéphanie Becker, David Tonnelet, Elodie Dos Santos, Claire Leroy, Mustafa Alani, Jean Rouvet, Marine Brousseau, Camille Giverne, Alexis Cuffel, Serge Jacquot, Arnaud Roucheux, Alice Veuiller, Nicolas Lecornu, Misa Eugene Norbert, Olivier Boyer, Hervé Tilly, Fabrice Jardin, Jean-Baptiste Latouche, Vincent Camus\",\"doi\":\"10.1002/hon.70139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <p>This retrospective, single-center study evaluated routine flow cytometry (FC) monitoring of CAR-T-cells in 45 patients with aggressive large B-cell lymphoma (LBCL). CAR-T-cells expansion was assessed from Day 0 to Month 12. Peak expansion occurred on Day 7 after axi-cel (median 39.3% of total lymphocytes; 87 cells/mm<sup>3</sup>) and Day 10 for tisa-cel (median 8.1%; 33.2 cells/mm<sup>3</sup>). Greater CAR-T-cells expansion was associated with immune-related toxicity, with median peak levels reaching 52.8% in patients with grade 2 cytokine release syndrome (CRS) versus 6.6% in those without (<i>p</i> < 0.001) and 60.8% in patients with immune effector cell-associated neurotoxicity syndrome (ICANS) versus 15.3% in those without (<i>p</i> < 0.001). Prolonged cytopenia was observed in 65% of patients and more frequently among those with greater CAR-T-cells expansion. This study highlights FC as a practical tool for monitoring CAR-T-cells dynamics in routine practice, with potential implications for early toxicity risk assessment and personalized supportive care.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":\"43 6\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70139\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.70139\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Routine Monitoring of CAR-T-Cells Expansion and Persistence in Patients With Aggressive Large B-Cell Lymphoma by Flow Cytometry: A Single-Center Experience
This retrospective, single-center study evaluated routine flow cytometry (FC) monitoring of CAR-T-cells in 45 patients with aggressive large B-cell lymphoma (LBCL). CAR-T-cells expansion was assessed from Day 0 to Month 12. Peak expansion occurred on Day 7 after axi-cel (median 39.3% of total lymphocytes; 87 cells/mm3) and Day 10 for tisa-cel (median 8.1%; 33.2 cells/mm3). Greater CAR-T-cells expansion was associated with immune-related toxicity, with median peak levels reaching 52.8% in patients with grade 2 cytokine release syndrome (CRS) versus 6.6% in those without (p < 0.001) and 60.8% in patients with immune effector cell-associated neurotoxicity syndrome (ICANS) versus 15.3% in those without (p < 0.001). Prolonged cytopenia was observed in 65% of patients and more frequently among those with greater CAR-T-cells expansion. This study highlights FC as a practical tool for monitoring CAR-T-cells dynamics in routine practice, with potential implications for early toxicity risk assessment and personalized supportive care.
期刊介绍：
Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:
-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders
-Diagnostic investigations, including imaging and laboratory assays
-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases
-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies
-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.
Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
